H5N1 vaccines in humans

Virus Research

Volumn 178, Issue 1, 2013, Pages 78-98

  Baz, Mariana ^a   Luke, Catherine J ^a   Cheng, Xing ^b   Jin, Hong ^b   Subbarao, Kanta ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b MEDIMMUNE   (United States)

Author keywords

Adjuvants; Clinical trials; H5N1; Pandemic; Vaccine strategies

Indexed keywords

ADENOVIRUS VACCINE; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ALUMINUM POTASSIUM SULFATE; AS 03; AS03; CHITOSAN; DNA VACCINE; EGG DERIVED WHOLE VIRUS VACCINE; INACTIVATED VACCINE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MIFAMURTIDE; PLACEBO; RECOMBINANT VACCINE; SPLIT VIRION VACCINE; UNCLASSIFIED DRUG; VAXFECTIN; VIRUS LIKE PARTICLE VACCINE; WATER OIL CREAM; WHOLE VIRION VACCINE;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIBODY TITER; APPLICATION SITE REACTION; ARTICLE; AVIAN INFLUENZA; CELLULAR IMMUNITY; CLADISTICS; CLINICAL TRIAL (TOPIC); CROSS REACTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; GENETIC REASSORTMENT; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; LICENSING; MULTICENTER STUDY (TOPIC); NARCOLEPSY; OPTIMAL DRUG DOSE; PANDEMIC INFLUENZA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLANT VIRUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE GENETICS; SEASONAL INFLUENZA; SEROCONVERSION; SINGLE DRUG DOSE; VIRUS INACTIVATION; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALIA; AVES; ORTHOMYXOVIRIDAE;

ADJUVANTS; CLINICAL TRIALS; H5N1; PANDEMIC; VACCINE STRATEGIES;

ANIMALS; ANTIBODIES, VIRAL; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 84887624476     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2013.05.006     Document Type: Article

References (194)

1. Abdel-Ghafar A.N., Chotpitayasunondh T., Gao Z., Hayden F.G., Nguyen D.H., de Jong M.D., Naghdaliyev A., Peiris J.S., Shindo N., Soeroso S., Uyeki T.M. Update on avian influenza A (H5N1) virus infection in humans. The New England Journal of Medicine 2008, 358(3):261-273.
2. Alexander J., Ward S., Mendy J., Manayani D.J., Farness P., Avanzini J.B., Guenther B., Garduno F., Jow L., Snarsky V., Ishioka G., Dong X., Vang L., Newman M.J., Mayall T. Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. PLoS One 2012, 7(2):e31177.
3. Andrewes C.H., Laidlaw P.P., Smith W. The susceptibility of mice to the viruses of human and swine influenza. Lancet 1934, 224:859-862.
4. Aucouturier J., Dupuis L., Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001, 19(17-19):2666-2672.
5. Banzhoff A., Gasparini R., Laghi-Pasini F., Staniscia T., Durando P., Montomoli E., Capecchi P.L., di Giovanni P., Sticchi L., Gentile C., Hilbert A., Brauer V., Tilman S., Podda A. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009, 4(2):e4384.
6. Baras B., Stittelaar K.J., Simon J.H., Thoolen R.J., Mossman S.P., Pistoor F.H., van Amerongen G., Wettendorff M.A., Hanon E., Osterhaus A.D. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 2008, 3(1):e1401.
7. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K., Graham I.L., Noah D.L., He F., Hill H. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. Journal of Infectious Diseases 2008, 197(5):667-675.
8. Berthoud T.K., Hamill M., Lillie P.J., Hwenda L., Collins K.A., Ewer K.J., Milicic A., Poyntz H.C., Lambe T., Fletcher H.A., Hill A.V., Gilbert S.C. Potent CD8+T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clinical Infectious Diseases 2011, 52(1):1-7.
9. Bosch F.X., Orlich M., Klenk H.D., Rott R. The structure of the hemagglutinin, a determinant for the pathogenicity of influenza viruses. Virology 1979, 95:197-207.
10. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., Hoschler K., Zambon M.C. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006, 367(9523):1657-1664.
11. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., Kumar N.M., Pushko P., Smith G., Tumpey T.M., Ross T.M. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008, 3(1):e1501.
12. Bright R.A., Carter D.M., Daniluk S., Toapanta F.R., Ahmad A., Gavrilov V., Massare M., Pushko P., Mytle N., Rowe T., Smith G., Ross T.M. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25(19):3871-3878.
13. Brown E.G. Increased virulence of a mouse-adapted variant of Influenza A/FM/1/47 virus is controlled by mutations in genome segments 4, 5, 7 and 8. Journal of Virology 1990, 64:4523-4533.
14. Chen G.L., Lamirande E.W., Yang C.F., Jin H., Kemble G., Subbarao K. Evaluation of replication and cross-reactive antibody responses of H2 subtype influenza viruses in mice and ferrets. Journal of Virology 2010, 84(15):7695-7702.
15. Chen H., Matsuoka Y., Chen Q., Cox N.J., Murphy B.R., Subbarao K. Generation and characterization of an H9N2 cold-adapted reassortant as a vaccine candidate. Avian Diseases 2003, 47(3 Suppl.):1127-1130.
16. Chen H., Smith G.J., Li K.S., Wang J., Fan X.H., Rayner J.M., Vijaykrishna D., Zhang J.X., Zhang L.J., Guo C.T., Cheung C.L., Xu K.M., Duan L., Huang K., Qin K., Leung Y.H., Wu W.L., Lu H.R., Chen Y., Xia N.S., Naipospos T.S., Yuen K.Y., Hassan S.S., Bahri S., Nguyen T.D., Webster R.G., Peiris J.S., Guan Y. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proceedings of the National Academy of Sciences United States of America 2006, 103(8):2845-2850.
17. Chen Y., Qin K., Wu W.L., Li G., Zhang J., Du H., Ng M.H., Shih J.W., Peiris J.S., Guan Y., Chen H., Xia N. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. Journal of Infectious Diseases 2009, 199(1):49-58.
18. Chen Z., Wang W., Zhou H., Suguitan A.L., Shambaugh C., Kim L., Zhao J., Kemble G., Jin H. Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. Journal of Virology 2010, 84(1):44-51.
19. Cheng X., Zengel J.R., Xu Q., Jin H. Surface glycoproteins of influenza A H3N2 virus modulate virus replication in the respiratory tract of ferrets. Virology 2012, 432(1):91-98.
20. Chirkova T.V., Naykhin A.N., Petukhova G.D., Korenkov D.A., Donina S.A., Mironov A.N., Rudenko L.G. Memory T-cell immune response in healthy young adults vaccinated with live attenuated influenza A (H5N2) vaccine. Clinical and Vaccine Immunology 2011, 18(10):1710-1718.
21. CHMP Committee for Proprietary Medicinal Products. Note for Guidance on Harmonisation of Requirements for Influenza Vaccines (CPMP/BWP 214/96) 1997, European Agency for the Evaluation of Medicinal Products, London.
22. Chotpitayasunondh T., Thisyakorn U., Pancharoen C., Pepin S., Nougarede N. Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children. PLoS One 2008, 3(12):e4028.
23. Clements M.L., Murphy B.R. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. Journal of Clinical Microbiology 1986, 23(1):66-72.
24. Corti D., Voss J., Gamblin S.J., Codoni G., Macagno A., Jarrossay D., Vachieri S.G., Pinna D., Minola A., Vanzetta F., Silacci C., Fernandez-Rodriguez B.M., Agatic G., Bianchi S., Giacchetto-Sasselli I., Calder L., Sallusto F., Collins P., Haire L.F., Temperton N., Langedijk J.P., Skehel J.J., Lanzavecchia A. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 333(6044):850-856.
25. Coudeville L., Bailleux F., Riche B., Megas F., Andre P., Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Medical Research Methodology 2010, 10:18.
26. Cox N.J., Subbarao K. Influenza. Lancet 1999, 354(9186):1277-1282.
27. Crotty S., Ahmed R. Immunological memory in humans. Seminars in Immunology 2004, 16(3):197-203.
28. Crowe B.A., Bruhl P., Gerencer M., Schwendinger M.G., Pilz A., Kistner O., Koelling-Schlebusch K., Aichinger G., Singer J., Zeitlinger M., Muller M., Ehrlich H., Barrett P.N. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. Vaccine 2010, 29(2):166-173.
29. D'Aoust M.A., Couture M.M., Charland N., Trepanier S., Landry N., Ors F., Vezina L.P. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnology Journal 2010, 8(5):607-619.
30. D'Aoust M.A., Lavoie P.O., Couture M.M., Trepanier S., Guay J.M., Dargis M., Mongrand S., Landry N., Ward B.J., Vezina L.P. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnology Journal 2008, 6(9):930-940.
31. D'Aoust, M.-A., Couture, M., Ors, F., Trepanier, S., Lavoie, P.-O., Dargis, M., Vezina, L.-P., 2009. Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin. International Patent application WO2009/076778.
32. Dauvilliers Y., Montplaisir J., Cochen V., Desautels A., Einen M., Lin L., Kawashima M., Bayard S., Monaca C., Tiberge M., Filipini D., Tripathy A., Nguyen B.H., Kotagal S., Mignot E. Post-H1N1 narcolepsy-cataplexy. Sleep 2010, 33(11):1428-1430.
33. de Jong J.C., Palache A.M., Beyer W.E., Rimmelzwaan G.F., Boon A.C., Osterhaus A.D. Haemagglutination-inhibiting antibody to influenza virus. Developmental Biology (Basel) 2003, 115:63-73.
34. de Jong M.D., Tran T.T., Truong H.K., Vo M.H., Smith G.J., Nguyen V.C., Bach V.C., Phan T.Q., Do Q.H., Guan Y., Peiris J.S., Tran T.H., Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. The New England Journal of Medicine 2005, 353(25):2667-2672.
35. Diez-Domingo J., Garces-Sanchez M., Baldo J.M., Planelles M.V., Ubeda I., JuBert A., Mares J., Moris P., Garcia-Corbeira P., Drame M., Gillard P. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Pediatric Infectious Disease Journal 2010, 29(6):e35-e46.
36. Droebner K., Haasbach E., Fuchs C., Weinzierl A.O., Stevanovic S., Buttner M., Planz O. Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain. Vaccine 2008, 26(52):6965-6974.
37. Dybing J.K., Schultz-Cherry S., Swayne D.E., Suarez D.L., Perdue M.L. Distinct pathogenesis of Hong Kong-origin H5N1 viruses in mice compared to that of other highly pathogenic H5 avian influenza viruses. Journal of Virology 2000, 74:1443-1450.
38. Ehrlich H.J., Muller M., Fritsch S., Zeitlinger M., Berezuk G., Low-Baselli A., van der Velden M.V., Pollabauer E.M., Maritsch F., Pavlova B.G., Tambyah P.A., Oh H.M., Montomoli E., Kistner O., Noel Barrett P. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. Journal of Infectious Diseases 2009, 200(7):1113-1118.
39. Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., Fisher D., Berezuk G., Fritsch S., Low-Baselli A., Vartian N., Bobrovsky R., Pavlova B.G., Pollabauer E.M., Kistner O., Barrett P.N. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. The New England Journal of Medicine 2008, 358(24):2573-2584.
40. Ekiert D.C., Bhabha G., Elsliger M.A., Friesen R.H., Jongeneelen M., Throsby M., Goudsmit J., Wilson I.A. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324(5924):246-251.
41. Ekiert D.C., Friesen R.H., Bhabha G., Kwaks T., Jongeneelen M., Yu W., Ophorst C., Cox F., Korse H.J., Brandenburg B., Vogels R., Brakenhoff J.P., Kompier R., Koldijk M.H., Cornelissen L.A., Poon L.L., Peiris M., Koudstaal W., Wilson I.A., Goudsmit J. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011, 333(6044):843-850.
42. EMEA Guideline on Dossier Structure and Content for Pandemic Influenza Vaccine Marketing Authorisation Application (CPMP/VEG/4717/03) 2008, http://www.emea.europa.eu/pdfs/human/vwp/471703en.pdf.
43. Epstein S.L., Kong W.P., Misplon J.A., Lo C.Y., Tumpey T.M., Xu L., Nabel G.J. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005, 23(46-47):5404-5410.
44. Epstein S.L., Tumpey T.M., Misplon J.A., Lo C.Y., Cooper L.A., Subbarao K., Renshaw M., Sambhara S., Katz J.M. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerging Infectious Diseases 2002, 8(8):796-801.
45. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., Fu T.M., Joyce J., Przysiecki C.T., Keller P.M., Garsky V.M., Ionescu R., Rippeon Y., Shi L., Chastain M.A., Condra J.H., Davies M.E., Liao J., Emini E.A., Shiver J.W. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22(23-24):2993-3003.
46. Fazekas G., Martosne-Mendi R., Jankovics I., Szilvasy I., Vajo Z. Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains. Clinical and Vaccine Immunology 2009, 16(4):437-443.
47. FDA U.S. FDA Approves First U.S. Vaccine for Humans Against the Avian Influenza Virus H5N1 2007, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108892.htm.
48. FDA Guidance for Industry. Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines 2007, http://www.fda.gov/cber/gdlns/panfluvac.htm.
49. Ferguson N.M., Cummings D.A., Fraser C., Cajka J.C., Cooley P.C., Burke D.S. Strategies for mitigating an influenza pandemic. Nature 2006, 442(7101):448-452.
50. Fragapane E., Gasparini R., Schioppa F., Laghi-Pasini F., Montomoli E., Banzhoff A. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clinical and Vaccine Immunology 2010, 17(11):1817-1819.
51. Galli G., Hancock K., Hoschler K., DeVos J., Praus M., Bardelli M., Malzone C., Castellino F., Gentile C., McNally T., Del Giudice G., Banzhoff A., Brauer V., Montomoli E., Zambon M., Katz J., Nicholson K., Stephenson I. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proceedings of the National Academy of Sciences United States of America 2009, 106(19):7962-7967.
52. Gao P., Watanabe S., Ito T., Goto H., Wells K., McGregor M., Cooley A.J., Kawaoka Y. Biological heterogeneity, including systemic replication in mice, of H5N1 influenza A virus isolates from humans in Hong Kong. Journal of Virology 1999, 73:3184-3189.
53. Gao W., Soloff A.C., Lu X., Montecalvo A., Nguyen D.C., Matsuoka Y., Robbins P.D., Swayne D.E., Donis R.O., Katz J.M., Barratt-Boyes S.M., Gambotto A. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. Journal of Virology 2006, 80(4):1959-1964.
54. Garcon N., Vaughn D.W., Didierlaurent A.M. Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Review of Vaccines 2012, 11(3):349-366.
55. Gillim-Ross L., Santos C., Chen Z., Aspelund A., Yang C.F., Ye D., Jin H., Kemble G., Subbarao K. Avian influenza h6 viruses productively infect and cause illness in mice and ferrets. Journal of Virology 2008, 82(21):10854-10863.
56. Goji N.A., Nolan C., Hill H., Wolff M., Noah D.L., Williams T.B., Rowe T., Treanor J.J. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. Journal of Infectious Diseases 2008, 198(5):635-641.
57. Gorse G.J., Campbell M.J., Otto E.E., Powers D.C., Chambers G.W., Newman F.K. Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine. Journal of Infectious Diseases 1995, 172(1):1-10.
58. Govorkova E.A., Rehg J.E., Krauss S., Yen H.L., Guan Y., Peiris M., Nguyen T.D., Hahn T.H., Puthavathana P., Long H.T., Buranathai C., Lim W., Webster R.G., Hoffmann E. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. Journal of Virology 2005, 79:2191-2198.
59. Grgacic E.V., Anderson D.A. Virus-like particles: passport to immune recognition. Methods 2006, 40(1):60-65.
60. Gruber W.C. The role of live influenza vaccines in children. Vaccine 2002, 20(Suppl. 2):S66-S73.
61. Gurwith M., Lock M., Taylor E.M., Ishioka G., Alexander J., Mayall T., Ervin J.E., Greenberg R.N., Strout C., Treanor J.J., Webby R., Wright P.F. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infectious Diseases 2013, 13(3):238-250.
62. Guy B. The perfect mix: recent progress in adjuvant research. Nature Reviews Microbiology 2007, 5(7):505-517.
63. Harrison W.T. Some observations on the use of alum precipitated diphtheria toxoid. American Journal of Public Health and the Nation's Health 1935, 25(3):298-300.
64. Hatta M., Gao P., Halfmann P., Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 2001, 293:1840-1842.
65. Hem S.L., Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Review of Vaccines 2007, 6(5):685-698.
66. HHS U. US Department of Health and Human Services 2006 Pandemic Influenza Plan 2006, See. http://www.hhs.gov/pandemicflu/plan/.
67. Hinshaw V.S., Webster R.G., Easterday B.C., Bean W.J. Replication of avian influenza A viruses in mammals. Infection and Immunity 1981, 34:354-361.
68. Hoelscher M.A., Garg S., Bangari D.S., Belser J.A., Lu X., Stephenson I., Bright R.A., Katz J.M., Mittal S.K., Sambhara S. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006, 367(9509):475-481.
69. Hoelscher M.A., Jayashankar L., Garg S., Veguilla V., Lu X., Singh N., Katz J.M., Mittal S.K., Sambhara S. New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. Clinical Pharmacology and Therapeutics 2007, 82(6):665-671.
70. Jackson S., Van Hoeven N., Chen L.M., Maines T.R., Cox N.J., Katz J.M., Donis R.O. Reassortment between avian H5N1 and human H3N2 influenza viruses in ferrets: a public health risk assessment. Journal of Virology 2009, 83(16):8131-8140.
71. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. Journal of Immunology 2004, 172(9):5598-5605.
72. Jelley-Gibbs D.M., Strutt T.M., McKinstry K.K., Swain S.L. Influencing the fates of CD4 T cells on the path to memory: lessons from influenza. Immunology and Cell Biology 2008, 86(4):343-352.
73. Jennings L.C., Monto A.S., Chan P.K., Szucs T.D., Nicholson K.G. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infectious Diseases 2008, 8(10):650-658.
74. Jones S., Evans K., McElwaine-Johnn H., Sharpe M., Oxford J., Lambkin-Williams R., Mant T., Nolan A., Zambon M., Ellis J., Beadle J., Loudon P.T. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 2009, 27(18):2506-2512.
75. Joseph T., McAuliffe J., Lu B., Jin H., Kemble G., Subbarao K. Evaluation of replication and pathogenicity of avian influenza a H7 subtype viruses in a mouse model. Journal of Virology 2007, 81(19):10558-10566.
76. Kandun I.N., Wibisono H., Sedyaningsih E.R., Yusharmen, Hadisoedarsuno W., Purba W., Santoso H., Septiawati C., Tresnaningsih E., Heriyanto B., Yuwono D., Harun S., Soeroso S., Giriputra S., Blair P.J., Jeremijenko A., Kosasih H., Putnam S.D., Samaan G., Silitonga M., Chan K.H., Poon L.L., Lim W., Klimov A., Lindstrom S., Guan Y., Donis R., Katz J., Cox N., Peiris M., Uyeki T.M. Three Indonesian clusters of H5N1 virus infection in 2005. The New England Journal of Medicine 2006, 355(21):2186-2194.
77. Kang S.M., Yoo D.G., Lipatov A.S., Song J.M., Davis C.T., Quan F.S., Chen L.M., Donis R.O., Compans R.W. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One 2009, 4(3):e4667.
78. Karron R.A., Callahan K., Luke C., Thumar B., McAuliffe J., Schappell E., Joseph T., Coelingh K., Jin H., Kemble G., Murphy B.R., Subbarao K. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. Journal of Infectious Diseases 2009, 199(5):711-716.
79. Karron R.A., Talaat K., Luke C., Callahan K., Thumar B., Dilorenzo S., McAuliffe J., Schappell E., Suguitan A., Mills K., Chen G., Lamirande E., Coelingh K., Jin H., Murphy B.R., Kemble G., Subbarao K. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009, 27(36):4953-4960.
80. Kawaoka Y., Webster R.G. Sequence requirements for cleavage activation of influenza virus hemagglutinin expressed in mammalian cells. Proceedings of the National Academy of Sciences United States of America 1988, 85:324-328.
81. Kelly D.F., Pollard A.J., Moxon E.R. Immunological memory: the role of B cells in long-term protection against invasive bacterial pathogens. JAMA 2005, 294(23):3019-3023.
82. Kendal A.P., Maassab H.F., Alexandrova G.I., Ghendon Y.Z. Development of cold-adapted recombinant live, attenuated influenza A vaccines in the U.S.A. and U.S.S.R. Antiviral Research 1981, 1:339-365.
83. Khurana S., Chearwae W., Castellino F., Manischewitz J., King L.R., Honorkiewicz A., Rock M.T., Edwards K.M., Del Giudice G., Rappuoli R., Golding H. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Science Translational Medicine 2010, 2(15):15ra5.
84. Khurana S., Wu J., Verma N., Verma S., Raghunandan R., Manischewitz J., King L.R., Kpamegan E., Pincus S., Smith G., Glenn G., Golding H. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. Journal of Virology 2011, 85(21):10945-10954.
85. Kim J.H., Jacob J. DNA vaccines against influenza viruses. Current Topics in Microbiology and Immunology 2009, 333:197-210.
86. Kost T.A., Condreay J.P., Jarvis D.L. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nature Biotechnology 2005, 23(5):567-575.
87. Laddy D.J., Yan J., Kutzler M., Kobasa D., Kobinger G.P., Khan A.S., Greenhouse J., Sardesai N.Y., Draghia-Akli R., Weiner D.B. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One 2008, 3(6):e2517.
88. Lakey D.L., Treanor J.J., Betts R.F., Smith G.E., Thompson J., Sannella E., Reed G., Wilkinson B.E., Wright P.F. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. Journal of Infectious Diseases 1996, 174(4):838-841.
89. Lalor P.A., Webby R.J., Morrow J., Rusalov D., Kaslow D.C., Rolland A., Smith L.R. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. Journal of Infectious Diseases 2008, 197(12):1643-1652.
90. Landry N., Ward B.J., Trepanier S., Montomoli E., Dargis M., Lapini G., Vezina L.P. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010, 5(12):e15559.
91. Langley J.M., Risi G., Caldwell M., Gilderman L., Berwald B., Fogarty C., Poling T., Riff D., Baron M., Frenette L., Sheldon E., Collins H., Shepard M., Dionne M., Brune D., Ferguson L., Vaughn D., Li P., Fries L. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. Journal of Infectious Diseases 2011, 203(12):1729-1738.
92. Latham T., Galarza J.M. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. Journal of Virology 2001, 75(13):6154-6165.
93. Layton R.C., Gigliotti A., Armijo P., Myers L., Knight J., Donart N., Pyles J., Vaughan S., Plourde J., Fomukong N., Harrod K.S., Gao P., Koster F. Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret. PLoS One 2011, 6(6):e20641.
94. Le Q.M., Kiso M., Someya K., Sakai Y.T., Nguyen T.H., Nguyen K.H., Pham N.D., Ngyen H.H., Yamada S., Muramoto Y., Horimoto T., Takada A., Goto H., Suzuki T., Suzuki Y., Kawaoka Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005, 437(7062):1108.
95. Ledgerwood J.E., Wei C.J., Hu Z., Gordon I.J., Enama M.E., Hendel C.S., McTamney P.M., Pearce M.B., Yassine H.M., Boyington J.C., Bailer R., Tumpey T.M., Koup R.A., Mascola J.R., Nabel G.J., Graham B.S. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infectious Diseases 2011, 11(12):916-924.
96. Leroux-Roels I., Bernhard R., Gerard P., Drame M., Hanon E., Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008, 3(2):e1665.
97. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., Devaster J.M., Leroux-Roels G. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370(9587):580-589.
98. Levesque P.M., Foster K., de Alwis U. Association between immunogenicity and adsorption of a recombinant Streptococcus pneumoniae vaccine antigen by an aluminum adjuvant. Human Vaccines 2006, 2(2):74-77.
99. Levie K., Leroux-Roels I., Hoppenbrouwers K., Kervyn A.D., Vandermeulen C., Forgus S., Leroux-Roels G., Pichon S., Kusters I. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. Journal of Infectious Diseases 2008, 198(5):642-649.
100. Levine M.M., Hughes T.P., Simon P., O'Donnell S., Grauel S., Levine S.G. Monovalent inactivated A/New Jersey/8/76 (Hsw1N1) vaccine in healthy children aged three to five years. Journal of Infectious Diseases 1977, 136(Suppl):S571-S574.
101. Lillie P.J., Berthoud T.K., Powell T.J., Lambe T., Mullarkey C., Spencer A.J., Hamill M., Peng Y., Blais M.E., Duncan C.J., Sheehy S.H., Havelock T., Faust S.N., Williams R.L., Gilbert A., Oxford J., Dong T., Hill A.V., Gilbert S.C. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clinical Infectious Diseases 2012, 55(1):19-25.
102. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., Gao Q., Zhang Z., Liu Y., Wang Z., Yang M., Sun R., Li C., Lin S., Ji M., Liu Y., Wang X., Wood J., Feng Z., Wang Y., Yin W. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006, 368(9540):991-997.
103. Lin J.T., Li C.G., Wang X., Su N., Liu Y., Qiu Y.Z., Yang M., Chen J.T., Fang H.H., Dong X.P., Yin W.D., Feng Z.J. Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine. Journal of Infectious Diseases 2009, 199(2):184-187.
104. Ludwig C., Wagner R. Virus-like particles-universal molecular toolboxes. Current Opinion in Biotechnology 2007, 18(6):537-545.
105. Luke C.J., Subbarao K. The role of animal models in influenza vaccine research. Influenza Vaccines for the Future 2011, 223-272. Springer, Basel. 2nd ed. R. Rappuoli, G. Del Giudice (Eds.).
106. Maassab H.F. Plaque formation of influenza virus at 25 degrees C. Nature 1968, 219(5154):645-646.
107. Mahmood K., Bright R.A., Mytle N., Carter D.M., Crevar C.J., Achenbach J.E., Heaton P.M., Tumpey T.M., Ross T.M. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 2008, 26(42):5393-5399.
108. Maines T.R., Lu X.H., Erb S.M., Edwards L., Guarner J., Greer P.W., Nguyen D.C., Szretter K.J., Chen L.M., Thawatsupha P., Chittaganpitch M., Waicharoen S., Nguyen D.T., Nguyen T.H., Nguyen H.H., Kim J.H., Hoang L.T., Kang C., Phuong L.S., Lim W., Zaki S., Donis R.O., Cox N.J., Katz J.M., Tumpey T.M. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. Journal of Virology 2005, 79:11788-11800.
109. McKinstry K.K., Strutt T.M., Kuang Y., Brown D.M., Sell S., Dutton R.W., Swain S.L. Memory CD4+T cells protect against influenza through multiple synergizing mechanisms. Journal of Clinical Investigation 2012, 122(8):2847-2856.
110. McMichael A.J., Gotch F.M., Noble G.R., Beare P.A. Cytotoxic T-cell immunity to influenza. The New England Journal of Medicine 1983, 309(1):13-17.
111. Miller E., Andrews N., Stellitano L., Stowe J., Winstone A.M., Shneerson J., Verity C. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013, 346:f794.
112. Morel S., Didierlaurent A., Bourguignon P., Delhaye S., Baras B., Jacob V., Planty C., Elouahabi A., Harvengt P., Carlsen H., Kielland A., Chomez P., Garcon N., Van Mechelen M. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29(13):2461-2473.
113. Morens D.M., Subbarao K., Taubenberger J.K. Engineering H5N1 avian influenza viruses to study human adaptation. Nature 2012, 486(7403):335-340.
114. Moris P., van der Most R., Leroux-Roels I., Clement F., Drame M., Hanon E., Leroux-Roels G.G., Van Mechelen M. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. Journal of Clinical Immunology 2011, 31(3):443-454.
115. Murphy B.R., Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunology 2002, 15(2):295-323.
116. Nichol K.L., Treanor J.J. Vaccines for seasonal and pandemic influenza. Journal of Infectious Diseases 2006, 194(Suppl. 2):S111-S118.
117. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., Zambon M.C. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357(9272):1937-1943.
118. Nicholson K.G., Tyrrell D.A., Harrison P., Potter C.W., Jennings R., Clark A., Schild G.C., Wood J.M., Yetts R., Seagroatt V., Huggins A., Anderson S.G. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. Journal of Biological Standardization 1979, 7(2):123-136.
119. Ninomiya A., Imai M., Tashiro M., Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 2007, 25(18):3554-3560.
120. Nohynek H., Jokinen J., Partinen M., Vaarala O., Kirjavainen T., Sundman J., Himanen S.L., Hublin C., Julkunen I., Olsen P., Saarenpaa-Heikkila O., Kilpi T. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012, 7(3):e33536.
121. Nolan T., Richmond P.C., Formica N.T., Hoschler K., Skeljo M.V., Stoney T., McVernon J., Hartel G., Sawlwin D.C., Bennet J., Ryan D., Basser R.L., Zambon M.C. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008, 26(50):6383-6391.
122. Nolan T.M., Richmond P.C., Skeljo M.V., Pearce G., Hartel G., Formica N.T., Hoschler K., Bennet J., Ryan D., Papanaoum K., Basser R.L., Zambon M.C. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 2008, 26(33):4160-4167.
123. O'Hagan D.T., Ott G.S., De Gregorio E., Seubert A. The mechanism of action of MF59-an innately attractive adjuvant formulation. Vaccine 2012, 30(29):4341-4348.
124. OIE Update on Avian Influenza in Animals (type H5) 2008, http://www.oie.int/downld/AVIAN%20INFLUENZA/A_AI-Asia.htm.
125. Palese P., Wang T.T. H5N1 influenza viruses: facts, not fear. Proceedings of the National Academy of Sciences United States of America 2012, 109(7):2211-2213.
126. Park K.S., Lee J., Ahn S.S., Byun Y.H., Seong B.L., Baek Y.H., Song M.S., Choi Y.K., Na Y.J., Hwang I., Sung Y.C., Lee C.G. Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge. Virology 2009, 395(2):182-189.
127. Parks C.L., Latham T., Cahill A., O'Neill R., Passarotti E., Buonagurio C.J., Bechert D.A., D'Arco T.M., Neumann G.A., Destefano G., Arendt J., Obregon H.E., Shutyak J., Hamm L., Sidhu S., Zamb M.S., Udem T.J.S.A. Phenotypic properties resulting from directed gene segment reassortment between wild-type A/Sydney/5/97 influenza virus and the live attenuated vaccine strain. Virology 2007, 367(2):275-287.
128. Perrone L.A., Ahmad A., Veguilla V., Lu X., Smith G., Katz J.M., Pushko P., Tumpey T.M. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. Journal of Virology 2009, 83(11):5726-5734.
129. Podda A., Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Review of Vaccines 2003, 2(2):197-203.
130. Potter C.W., Oxford J.S. Determinants of immunity to influenza infection in man. British Medical Bulletin 1979, 35(1):69-75.
131. Powers D.C., McElhaney J.E., Florendo O.A., Manning M.C., Upshaw C.M., Bentley D.W., Wilkinson B.E. Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus. Journal of Infectious Diseases 1997, 175(2):342-351.
132. Price G.E., Soboleski M.R., Lo C.Y., Misplon J.A., Pappas C., Houser K.V., Tumpey T.M., Epstein S.L. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 2009, 27(47):6512-6521.
133. Pushko P., Tumpey T.M., Van Hoeven N., Belser J.A., Robinson R., Nathan M., Smith G., Wright D.C., Bright R.A. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 2007, 25(21):4283-4290.
134. Puthavathana P., Auewarakul P., Charoenying P.C., Sangsiriwut K., Pooruk P., Boonnak K., Khanyok R., Thawachsupa P., Kijphati R., Sawanpanyalert P. Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand. Journal of General Virology 2005, 86(Pt 2):423-433.
135. Roos R. Insect-Cell-Based flu Vaccine Looks Good in Clinical Trial 2007, http://www.cidrap.umn.edu/cidrap/content/influenza/panflu/news/apr1207cell.html.
136. Ruat C., Caillet C., Bidaut A., Simon J., Osterhaus A.D. Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. Journal of Virology 2008, 82(5):2565-2569.
137. Rudenko L., Desheva J., Korovkin S., Mironov A., Rekstin A., Grigorieva E., Donina S., Gambaryan A., Katlinsky A. Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials). Influenza and Other Respiratory Viruses 2008, 2(6):203-209.
138. Rumke H.C., Bayas J.M., de Juanes J.R., Caso C., Richardus J.H., Campins M., Rombo L., Duval X., Romanenko V., Schwarz T.F., Fassakhov R., Abad-Santos F., von Sonnenburg F., Drame M., Sanger R., Ballou W.R. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008, 26(19):2378-2388.
139. SAGE Use of Licensed H5N1 Influenza Vaccines in the Interpandemic Period. Report of the H5N1 SAGE Working Group to the April 2009 Meeting of the Strategic Advisory Group of Experts 2009, http://www.who.int/immunization/sage/SAGE_H5N1_26Mayb.pdf.
140. Salk J.E. Reactions to concentrated influenza virus vaccines. Journal of Immunology 1948, 58(4):369-395.
141. Schotsaert M., De Filette M., Fiers W., Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Review of Vaccines 2009, 8(4):499-508.
142. Schultze V., D'Agosto V., Wack A., Novicki D., Zorn J., Hennig R. Safety of MF59 adjuvant. Vaccine 2008, 26(26):3209-3222.
143. Shoji Y., Chichester J.A., Bi H., Musiychuk K., de la Rosa P., Goldschmidt L., Horsey A., Ugulava N., Palmer G.A., Mett V., Yusibov V. Plant-expressed HA as a seasonal influenza vaccine candidate. Vaccine 2008, 26(23):2930-2934.
144. Slepushkin V.A., Katz J.M., Black R.A., Gamble W.C., Rota P.A., Cox N.J. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995, 13(15):1399-1402.
145. Smith L.R., Wloch M.K., Ye M., Reyes L.R., Boutsaboualoy S., Dunne C.E., Chaplin J.A., Rusalov D., Rolland A.P., Fisher C.L., Al-Ibrahim M.S., Kabongo M.L., Steigbigel R., Belshe R.B., Kitt E.R., Chu A.H., Moss R.B. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010, 28(13):2565-2572.
146. Stephenson I., Bugarini R., Nicholson K.G., Podda A., Wood J.M., Zambon M.C., Katz J.M. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. Journal of Infectious Diseases 2005, 191(8):1210-1215.
147. Stephenson I., Heath A., Major D., Newman R.W., Hoschler K., Junzi W., Katz J.M., Weir J.P., Zambon M.C., Wood J.M. Reproducibility of serologic assays for influenza virus A (H5N1). Emerging Infectious Diseases 2009, 15(8):1252-1259.
148. Stephenson I., Nicholson K.G., Colegate A., Podda A., Wood J., Ypma E., Zambon M. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003, 21(15):1687-1693.
149. Stephenson I., Nicholson K.G., Hoschler K., Zambon M.C., Hancock K., DeVos J., Katz J.M., Praus M., Banzhoff A. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. The New England Journal of Medicine 2008, 359(15):1631-1633.
150. Subbarao K., Chen H., Swayne D., Mingay L., Fodor E., Brownlee G., Xu X., Lu X., Katz J., Cox N., Matsuoka Y. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003, 305(1):192-200.
151. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H., Perdue M., Swayne D., Bender C., Huang J., Hemphill M., Rowe T., Shaw M., Xu X., Fukuda K., Cox N. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998, 279(5349):393-396.
152. Suguitan A.L., Marino M.P., Desai P.D., Chen L.M., Matsuoka Y., Donis R.O., Jin H., Swayne D.E., Kemble G., Subbarao K. The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus. Virology 2009, 395(2):280-288.
153. Suguitan A.L., Matsuoka Y., Lau Y.F., Santos C.P., Vogel L., Cheng L.I., Orandle M., Subbarao K. The multibasic cleavage site of the hemagglutinin of highly pathogenic A/Vietnam/1203/2004 (H5N1) avian influenza virus acts as a virulence factor in a host-specific manner in mammals. Journal of Virology 2012, 86(5):2706-2714.
154. Suguitan A.L., McAuliffe J., Mills K.L., Jin H., Duke G., Lu B., Luke C.J., Murphy B., Swayne D.E., Kemble G., Subbarao K. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Medicine 2006, 3(9):e360.
155. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., Santelli E., Stec B., Cadwell G., Ali M., Wan H., Murakami A., Yammanuru A., Han T., Cox N.J., Bankston L.A., Donis R.O., Liddington R.C., Marasco W.A. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nature Structural & Molecular Biology 2009, 16(3):265-273.
156. Sullivan S.M., Doukas J., Hartikka J., Smith L., Rolland A. Vaxfect a versatile adjuvant for plasmid DNA-protein-based vaccines. Expert Opinion on Drug Delivery 2010, 7(12):1433-1446.
157. Takahashi Y. Memory B cells in systemic and mucosal immune response: implications for successful vaccination. Bioscience, Biotechnology, and Biochemistry 2007, 71(10):2358-2366.
158. Talaat K.R., Karron R.A., Liang P.H., McMahon B.A., Luke C.J., Thumar B., Chen G.L., Min J.Y., Lamirande E.W., Jin H., Coelingh K.L., Kemble G.W., Subbarao K. An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults. Influenza and Other Respiratory Viruses 2012.
159. Talaat K.R., Karron R.A., Luke C.J., Thumar B., McMahon B.A., Chen G.L., Lamirande E.W., Jin H., Coelingh K.L., Kemble G., Subbarao K. An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults. Vaccine 2011, 29(17):3144-3148.
160. Taylor P.M., Askonas B.A. Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology 1986, 58(3):417-420.
161. Thomas P.G., Keating R., Hulse-Post D.J., Doherty P.C. Cell-mediated protection in influenza infection. Emerging Infectious Diseases 2006, 12(1):48-54.
162. Throsby M., van den Brink E., Jongeneelen M., Poon L.L., Alard P., Cornelissen L., Bakker A., Cox F., van Deventer E., Guan Y., Cinatl J., ter Meulen J., Lasters I., Carsetti R., Peiris M., de Kruif J., Goudsmit J. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+memory B cells. PLoS One 2008, 3(12):e3942.
163. Tinsley T., Harrap K.A. Viruses of invertebrates; in: Fraenkel-Conrat H. Comprehensive Virology 1978, vol. 12:1-101. Plenum Press, New York.
164. Treanor J.J., Betts R.F., Smith G.E., Anderson E.L., Hackett C.S., Wilkinson B.E., Belshe R.B., Powers D.C. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. Journal of Infectious Diseases 1996, 173(6):1467-1470.
165. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. The New England Journal of Medicine 2006, 354(13):1343-1351.
166. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., Wolff M., Rabinovich G., Blackwelder W., Katz J.M. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001, 19(13-14):1732-1737.
167. Tutykhina I.L., Logunov D.Y., Shcherbinin D.N., Shmarov M.M., Tukhvatulin A.I., Naroditsky B.S., Gintsburg A.L. Development of adenoviral vector-based mucosal vaccine against influenza. Journal of Molecular Medicine (Berl) 2011, 89(4):331-341.
168. UKDH UK Department of Health. Pandemic Flu: A National Framework for Responding to an Influenza Pandemic 2011, See. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_080734.
169. Ungchusak K., Auewarakul P., Dowell S.F., Kitphati R., Auwanit W., Puthavathana P., Uiprasertkul M., Boonnak K., Pittayawonganon C., Cox N.J., Zaki S.R., Thawatsupha P., Chittaganpitch M., Khontong R., Simmerman J.M., Chunsutthiwat S. Probable person-to-person transmission of avian influenza A (H5N1). The New England Journal of Medicine 2005, 352(4):333-340.
170. Vajo Z., Kosa L., Szilvasy I., Pauliny Z., Bartha K., Visontay I., Kis A., Tarjan I., Rozsa N., Jankovics I. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children. Pediatric Infectious Disease Journal 2008, 27(12):1052-1056.
171. Vajo Z., Kosa L., Visontay I., Jankovics M., Jankovics I. Inactivated whole virus influenza A (H5N1) vaccine. Emerging Infectious Diseases 2007, 13(5):807-808.
172. Vajo Z., Wood J., Kosa L., Szilvasy I., Paragh G., Pauliny Z., Bartha K., Visontay I., Kis A., Jankovics I. A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development. Journal of Virology 2010, 84(3):1237-1242.
173. Vesikari T., Karvonen A., Tilman S., Borkowski A., Montomoli E., Banzhoff A., Clemens R. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 2010, 126(4):e762-e770.
174. Wan X.F., Nguyen T., Davis C.T., Smith C.B., Zhao Z.M., Carrel M., Inui K., Do H.T., Mai D.T., Jadhao S., Balish A., Shu B., Luo F., Emch M., Matsuoka Y., Lindstrom S.E., Cox N.J., Nguyen C.V., Klimov A., Donis R.O. Evolution of highly pathogenic H5N1 avian influenza viruses in Vietnam between 2001 and 2007. PLoS One 2008, 3(10):e3462.
175. Wang H., Feng Z., Shu Y., Yu H., Zhou L., Zu R., Huai Y., Dong J., Bao C., Wen L., Wang H., Yang P., Zhao W., Dong L., Zhou M., Liao Q., Yang H., Wang M., Lu X., Shi Z., Wang W., Gu L., Zhu F., Li Q., Yin W., Yang W., Li D., Uyeki T.M., Wang Y. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet 2008, 371(9622):1427-1434.
176. Wang T.T., Tan G.S., Hai R., Pica N., Petersen E., Moran T.M., Palese P. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathogens 2010, 6(2):e1000796.
177. Webby R.J., Perez D.R., Coleman J.S., Guan Y., Knight J.H., Govorkova E.A., McClain-Moss L.R., Peiris J.S., Rehg J.E., Tuomanen E.I., Webster R.G. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 2004, 363(9415):1099-1103.
178. WHO WHO Case Definitions For Human Infections with Influenza A(H5N1) Virus 2006, http://www.who.int/influenza/resources/documents/case_definition2006_08_29/en/index.html.
179. WHO Human cases of avian influenza A (H5N1) in North-West Frontier Province, Pakistan, October-November 2007. Weekly Epidemiological Record 2008, 83(40):359-364.
180. WHO Antigenic and genetic characteristics of influenza A(H5N1) viruses and candidate vaccine viruses developed for potential use in human vaccines. Weekly Epidemiological Record 2009, 84(41):432-436.
181. WHO World Health Organization. Pandemic Influenza Preparedness Framework for the Sharing of Influenza Viruses and Access to Vaccines and Other Benefits 2011, http://whqlibdoc.who.int/publications/2011/9789241503082_eng.pdf.
182. WHO Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. Weekly Epidemiological Record 2012, 87(11):97-108.
183. WHO Cumulative Number of Confirmed Human Cases of Avian Influenza A (H5N1) Reported to WHO 2012, WHO, Geneva, Available from URL:, (online). http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/index.html.
184. Wijnans L., Lecomte C., de Vries C., Weibel D., Sammon C., Hviid A., Svanstrom H., Molgaard-Nielsen D., Heijbel H., Dahlstrom L.A., Hallgren J., Sparen P., Jennum P., Mosseveld M., Schuemie M., van der Maas N., Partinen M., Romio S., Trotta F., Santuccio C., Menna A., Plazzi G., Moghadam K.K., Ferro S., Lammers G.J., Overeem S., Johansen K., Kramarz P., Bonhoeffer J., Sturkenboom M.C. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013, 31(8):1246-1254.
185. Wilkinson T.M., Li C.K., Chui C.S., Huang A.K., Perkins M., Liebner J.C., Lambkin-Williams R., Gilbert A., Oxford J., Nicholas B., Staples K.J., Dong T., Douek D.C., McMichael A.J., Xu X.N. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nature Medicine 2012, 18(2):274-280.
186. Wright P.F., Thompson J., Vaughn W.K., Folland D.S., Sell S.H., Karzon D.T. Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. Journal of Infectious Diseases 1977, 136(Suppl):S731-S741.
187. Wu J., Fang H.H., Chen J.T., Zhou J.C., Feng Z.J., Li C.G., Qiu Y.Z., Liu Y., Lu M., Liu L.Y., Dong S.S., Gao Q., Zhang X.M., Wang N., Yin W.D., Dong X.P. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clinical Infectious Diseases 2009, 48(8):1087-1095.
188. Wu J., Liu S.Z., Dong S.S., Dong X.P., Zhang W.L., Lu M., Li C.G., Zhou J.C., Fang H.H., Liu Y., Liu L.Y., Qiu Y.Z., Gao Q., Zhang X.M., Chen J.T., Zhong X., Yin W.D., Feng Z.J. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial. Vaccine 2010, 28(38):6221-6227.
189. Xu Q., Wang W., Cheng X., Zengel J., Jin H. Influenza H1N1 A/Solomon Island/3/06 virus receptor binding specificity correlates with virus pathogenicity, antigenicity, and immunogenicity in ferrets. Journal of Virology 2010, 84(10):4936-4945.
190. Yang P.C., Yu C.J., Chang S.C., Hsieh S.M., Drame M., Walravens K., Roman F., Gillard P. Safety and immunogenicity of a split-virion AS03A-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine in Taiwanese adults. Journal of the Formosan Medical Association 2012, 111(6):333-339.
191. Yap K.L., Ada G.L., McKenzie I.F. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 1978, 273(5659):238-239.
192. Yoshida R., Igarashi M., Ozaki H., Kishida N., Tomabechi D., Kida H., Ito K., Takada A. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathogens 2009, 5(3):e1000350.
193. Zangwill K.M., Treanor J.J., Campbell J.D., Noah D.L., Ryea J. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. Journal of Infectious Diseases 2008, 197(4):580-583.
194. Zitzow L.A., Rowe T., Morken T., Shieh W.J., Zaki S., Katz J.M. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. Journal of Virology 2002, 76:4420-4429.